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Abstract: The early events of severe sepsis set in
motion a cascade of events that significantly con-
tributes to the morbidity and mortality observed
during the first few days of this syndrome. Although
sepsis is a deadly, acute disease, survivors also
suffer long-term consequences. Clinical data un-
derscore subsequent high mortality rates associ-
ated with patients who are long-term survivors of
the acute septic episode. Within 1 year of surviving
severe sepsis, there is a 26% predicted mortality
rate, and many patients succumb to lung compli-
cations. In this review, we focus on the cellular and
molecular mechanisms that dictate the longer-term
sequela of sepsis and related lung injury. We have
established a murine model of experimental sepsis
[cecal ligation and puncture (CLP)], which results
in an approximate 60% survival rate. Our studies
have demonstrated that these survivors are suscep-
tible to a fungal infection with 100% mortality
when challenged 3 days or 15 days post-recovery
from the initial CLP. This increased mortality cor-
relates with changes in cytokines and Toll-like re-
ceptor expression and alterations in lung leukocyte
populations. We hypothesize that the lung becomes
predisposed to nosocomial infections for extended
periods of time after severe sepsis via mechanisms
that include alterations in inflammatory cytokines
and an increase in immunomodulatory chemo-
kines, such as monocyte chemoattractant pro-
tein-1 and C10. These mediators may alter the
innate-immune response by affecting dendritic
cells and macrophages, which could provide a
mechanism for the immunosuppression observed
following sepsis. J. Leukoc. Biol. 75: 408–412;
2004.
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INTRODUCTION
General consensus supports the idea that the acute inflamma-
tory response is intimately linked to innate immunity and
occurs over a relatively restricted chronological period. This
traditional notion of the limited time frame of a functional acute
inflammatory response has historically been supported by the
temporal expression of a set of inflammatory mediators and
leukocyte subpopulations. For example, within minutes of in
vivo lipopolysaccharide (LPS) challenge to the peritoneum,
mRNA expression for early response cytokines, such as tumor
necrosis factor  (TNF-), can be detected in mononuclear
phagocytic cells followed by the expression of more distal
cytokines and chemokines. This is followed by the recruitment
of polymorphonuclear cells, which occurs within hours. Over
the subsequent 24- to 48-h period, cytokine, chemokine, and
leukocyte levels will subside, and any alteration in local tissue
will be repaired [1, 2].
It is interesting that this scenario is dependent on the
quantity (amount) and quality (complexity of the challenge
composition) of the initial antigen or pathogen. An increase in
the amount of the challenge will result in a heightened, acute
cytokine and leukocyte response, and an increase in the com-
plexity may lead to a prolonged response. An additional factor
that determines the course of an acute inflammatory response is
the severity of the host’s response to the inciting agent. This
aspect of the response has important consequences for the
short-term course of the acute reaction but also appears to play
a key role regarding the host response to a subsequent chal-
lenge that occurs long after the initial severe acute reaction. An
interesting correlation exists between the severity of the initial,
acute inflammatory response and the ability of the host to deal
with a longer term, chronic challenge [3, 4].
One of the best examples of the chronic effects of severe
acute inflammation is presented by data modeled from human
septic populations. A variety of investigations have studied the
short-term (less than 30 days) sequelae of the septic response
and have reported mortalities of 30–50% [5]. Findings such as
these have resulted in labeling this syndrome as a deadly,
acute disease. However, additional investigations have noted
that the septic population is at a significant risk of dying of
nonseptic causes for up to 8 years after the initial hospitaliza-
tion [3, 4]. Thus, the initial, severe response sets in motion a
dysregulated, immune/inflammatory response, which has long-
lasting implications regarding how the host can respond to and
deal with other challenges. The chronic problems of severe
acute inflammation are not limited to disorders such as sepsis
but are found in a wide array of human diseases, including the
long-term consequences of ischemia/reperfusion injury post-
organ transplant [6], the alterations post-recovery from severe
respiratory syncycial virus (RSV) [7, 8], and the changes found
in burn and trauma injury [9, 10] (Table 1). This review will
focus on the chronicity of severe acute inflammatory responses.
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THE CHRONICITY OF SEVERE ACTUE
INFLAMMATION AND SUBSEQUENT
CLINICAL COMPLICATIONS
The above clinical data support the view that a number of
long-term consequences are associated with surviving severe
sepsis. It is interesting that this is not the only clinical example
of acute inflammation subsequently interphasing with chronic
inflammatory disorders. As shown in Table 1, there are a
number of clinical instances whereby an initial severe acute
inflammatory event has been associated with distal chronic
complications. Pediatricians who deal with severe acute RSV
infections in very young children are clearly mindful of the
longer term but ill-understood clinical complications, which
these children have in dealing with severe chronic asthma.
Transplant surgeons are aware of the problems that place a
solid organ transplant at long-term risk if during the initial
surgery, the donor organ has severe acute ischemia reperfusion
injury. Burn and trauma physicians are cognizant of the pa-
tients who recover from the acute and severe inflammatory
events of burn injury yet are susceptible to chronic clinical
complications later in life. One of the uniting themes of the
above clinical examples is that there appears to be a correla-
tion with the severity of the initial acute inflammatory event
that caused alterations in the innate and/or acquired immune
system, which is manifested for not only months but often years
after the initial severe insult. The mechanism(s) that are re-
sponsible for the chronic consequences of severe acute inflam-
mation are presently not well understood; however, incriminat-
ing factors likely include alterations in the normal levels and
activity of chemokines, cytokines, Toll-like receptors (TLRs),
and dendritic cells (DCs).
CHEMOKINES IN CLINICAL AND
EXPERIMENTAL SEPSIS
Over the past decade, a number of chemokines have been
identified that possess interesting biological activities in innate
and acquired immune response. Although chemokines clearly
play a crucial role in the initiation and maintenance of inflam-
mation via leukocyte recruitment, these protein mediators are
involved in other immune-related processes, such as angiogen-
esis, cell activation, healing, repair, and end-stage fibrosis
[11]. Chemokines have been divided into four subfamilies
based on their unique sequence homology and the position of
cysteine residues in the protein; the CC and CXC chemokine
families comprise the largest groups with diverse activities
[11]. Elevations in numerous CXC and CC chemokines have
been detected in clinical diseases, such as asthma, pneumonia,
colitis, central nervous system infection, gastritis, and sepsis.
These clinical studies have provided the impetus to study the
role of chemokines in established animal models of human
diseases, including sepsis [12].
In this review, we focus on the putative role of chemokines
in the pulmonary immunosuppression following experimental
sepsis. Investigations into the long-term consequence of sepsis
in survivors, especially with regard to the fate of immune
activity of the lung, have been lacking, although clinical stud-
ies have demonstrated considerable morbidity and mortality
associated with these individuals. It is noteworthy that a num-
ber of clinical studies support the observation that the long-
term morbidity and mortality of sepsis patients are dependent
on the severity of the initial insult [3, 4]. These investigations
demonstrated that the more severe the initial septic event, the
more morbidity and mortality were found in these particular
patients. We propose that the immunosuppression associated
with sepsis is, in part, a result of the prolonged activities of
immunomodulatory chemokines such as CCL2 [monocyte che-
moattractant protein-1 (MCP-1)], CCL17 [thymus and activa-
tion-regulated chemokine (TARC)], and C10 (CCL6), all of
which are induced by interleukin (IL)-13 and IL-4. Thus, the
pulmonary immune response in septic patients may be inap-
propriately skewed toward the T helper cell type 2 (Th2)
cytokine pattern. This hypothesis is in keeping with published
data showing that chemokine receptors have been found to be
differentially associated with Th1/Th2 subsets [13], and CC
chemokines appear to alter the outcome of the immune re-
sponses through altering the balance of Th1 and Th2 immune
activation [14]. We contend that the balance of proinflamma-
tory and modulatory CXC and CC chemokines is critical fol-
lowing a septic challenge, as this balance drives the response
toward an efficient response (i.e., infection resolution) or to-
ward an exaggerated release of immunomodulatory chemokines
(i.e., inappropriate immune response and death). Herein, we
provide data and discussion regarding the manner in which
chemokines modulate the pulmonary innate-immune response
after sepsis.
IMMUNOSUPPRESION FOLLOWING SEPSIS
A major research focus of several laboratories, including our
own, is to elucidate the mechanisms that influence the devel-
oping, pathologic changes that occur during the initiation and
maintenance of experimental sepsis. We have learned a con-
siderable amount about the factors that initiate the early in-
flammatory events associated with sepsis, and these factors
include a number of proinflammatory cytokines (including IL-1
and TNF). However, less is known about the long-term effects
of sepsis on the immune system, particularly in the lung. This
paucity led us to develop a murine model of severe sepsis
induced by cecal ligation and puncture (CLP), a model that
more closely mimics the clinical scenario. Following CLP
surgery, C57Bl/6 mice were given 3 days of an antibiotic
treatment regiment, which increased survival from 0 to 60%.
TABLE 1. Chronic Complications Associated with Severe
Acute Inflammatory Responses
• Chronic and life-threatening complications after surviving severe
sepsis [3, 4]
• Chronic transplant rejection associated with initial severe
ischemia/reperfusion injury [6]
• Chronic asthma increases after severe acute inflammation
induced by respiratory syncial virus [7, 8]
• Chronic problems accompanying survival of severe acute
inflammation caused by severe burns [9, 10]
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The survivors were subsequently challenged with Aspergillus
fumigatus on the third day after CLP surgery. In this model,
CLP groups, but not the sham surgery group, were clearly
predisposed to the fungus challenge. The CLP survivors were
also susceptible to a bacterial challenge with Pseudomonas
aeruginosa (60% mortality) on the third day after CLP surgery.
It is interesting that in a similar manner, all mice that survived
the original septic episode died rapidly after a fungal challenge
on day 15 after CLP surgery.
An assessment of the lungs of the mice surviving sepsis and
receiving a subsequent fungal, pulmonary challenge demon-
strated an interesting immune conundrum. In the CLP group
that received A. fumigatus challenge, at day 3 or 15 post-
surgery, a significant increase in the recruitment of leukocytes
(i.e., macrophages and neutrophils) into the lung was apparent,
as compared with the sham control animals. It is interesting
that mice subjected to sham surgery effectively contained the
fungus (Fig. 1A), whereas CLP mice were clearly not able to
eliminate the fungal challenge, as evidenced by the presence of
A. fumigatus conidia (or spores) and hyphae (Fig. 1B). Fungal
growth to this degree is usually observed in severely immuno-
compromised patients or immunosuppressed animals [15–17].
These data suggest that a disconnect exists between the ex-
pression of inflammatory mediators needed to recruit leuko-
cytes to the lung and the ability of the recruited leukocytes to
destroy the fungal challenge.
This disconnect was confirmed by transmission electron
microscopic analysis of lung samples at day 2 after A. fumiga-
tus challenge in sham and CLP mice (Fig. 2). Dead or dying
conidia (i.e., ghosts) were apparent in macrophages and neu-
trophils from the sham group (Fig. 2A), but in the CLP group,
phagocytosed, intact conidia were observed (Fig. 2B). We also
observed numerous hyphal elements in the lung of the CLP
group but not in the sham group (Fig. 2C).
The reason for the impairment in the fungal killing in the
CLP group is not presently apparent and is the subject of
ongoing studies. Gene array analyses have revealed that a
number of proinflammatory [examples include the p35 subunit
of IL-12, IL-6, interferon (IFN), and IL-1] genes were up-
regulated in the sham group challenged with A. fumigatus
compared with the sham group challenged with saline. How-
ever, no difference in the expression of these genes was ob-
served in the CLP group challenged with the fungus compared
with the sham group challenged with fungus. It is interesting
that CCL2 transcript expression was greatly increased in CLP
mice challenged with A. fumigatus. This finding has led us to
investigate whether the sustained generation of CCL2 may lead
to the suppression of macrophage activation. In support of this
hypothesis are recent studies documenting that activated mac-
rophages can be divided into three heterogeneous groups with
distinct immunological functions. First, the “classic” or acti-
vated macrophage releases TNF, IL-1, IL-6, IL-12, and nitric
oxide (NO) and has the ability to kill and degrade intracellular
microorganism. Second, the “alternatively activated” macro-
phage releases IL-10 and IL-1ra, which does not produce NO,
protects the host from an overzealous inflammatory response,
and is involved in tissue repair. Third, the type II macrophage,
which releases large amounts of IL-10 and induces T cells to
produce IL-4, but this cell also produces IL-6 and TNF [18,
19]. The differential activation of macrophages may explain the
“paralysis” of these cells in sepsis. Supporting this concept is
Fig. 1. Histological section of the lung at day 2 after an A. fumigatus conidia
challenge in mice subjected to CLP 15 days previously. Sham (A) and CLP (B)
mice were injected intratracheally with 5  107 A. fumigatus conidia, killed at
day 2 after this fungal challenge, and the lung tissue were harvested and
processed by routine, histological techniques to evaluate the presence of
conidia and hyphae (black dots/arrows, ghost conidia in A and hyphae growth
in B). Original magnification, 1000. The slides were stained with Gomori-
methanamine-silver, a specific stain for fungus, which appears black in the
figure.
Fig. 2. Electron micrograph of the
lung of sham (A) and CLP (B and C)
groups challenged with A. fumigatus.
Mice were injected intratracheally
with 5  107 conidia of A. fumigatus,
killed at day 2 after fungus chal-
lenge, and the lung tissue was har-
vested and processed for transmis-
sion electron microscopy. (A) Neu-
trophil (P) from sham-operated
mouse with two conidia inside: a
dead conidia—ghost (G)—and a de-
graded conidia (C). (B) Neutrophil
from CLP-operated mouse with intact
conidia inside (C). (C) Hyphae (H) in
the lung of CLP mice with a macro-
phage (M) attached to the cell wall of the fungus. Original magnification, 2600.
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evidence that macrophages remain active after sepsis, but their
repertoire of mediators is shifted away from those best suited
for fighting pathogens [18, 19].
POTENTIAL STRATEGIES FOR OVERCOMING
IMMUNOSUPPRESSION
Chemokine modulation of TLRs in lung
Recent evidence shows that TLRs recognize specific pat-
terns of microbial components, and these receptors appear
to regulate innate and adaptive immunity. There are several
inherent levels of sophistication built into the TLRs, as
different microbial structures are recognized by different
TLRs. For example, TLR1 binds triacyl lipopeptides (bac-
teria, mycobacteria); TLR2 binds lipoprotein/lipopeptides,
lipoteichoic acid (Gram-positive bacteria), and zymosan
(fungus); TLR3 binds double-stranded RNA (virus); TLR4
binds LPS (Gram-negative bacteria); TLR5 binds flagellin
(bacteria); TLR6 binds diacyl lipopeptides (mycoplasma);
and TLR9 binds CpG DNA (bacteria). The ligands for TLR7,
TLR8, and TLR10 are presently unknown. Activation of
specific cells via TLRs can serve as potent signals for the
expression of a number of mediators necessary to initiate
and maintain an inflammatory response. In particular, the
activation of the TLR2 or TLR4 pathway increases the
expression of CXC (IL-8) and CC chemokines (regulated on
activation, normal T expressed and secreted and MCP-1)
[20, 21]. It is interesting that the expression of TLRs is not
limited to leukocytes, as fibroblast and epithelial cells have
been shown to have functional TLR2 and TLR4, and when
activated, these receptors are involved in the expression of
significant levels of chemokines [20, 22, 23]. The activation
of TLRs leading to chemokine production is likely an im-
portant step required to rapidly engage the innate-immune
response, thereby allowing the participation of specific leu-
kocytes in the inflammatory response. However, more recent
studies in our laboratory suggest that chemokines may ac-
count for the dysregulation of the TLR expression on mac-
rophages from CLP mice. The dynamic interaction between
chemokines and TLRs is likely an important cascade that
may ultimately control the host’s response to a foreign agent.
It is elucidating that the manner in which chemokines
regulate TLR expression may provide important clues to
effective therapies in sepsis.
Chemokine modulation of DC recruitment to lung
Determining the overall contribution of DCs to the immuno-
suppression after sepsis is an area of ongoing investigation.
Studies directed at the long-term fate of lung DCs are now
appearing in the literature. For example, Wysocka et al. [24]
showed that mice primed with LPS and then challenged with a
lower LPS dose contained a significant reduced number or
CD11chigh IL-12-producing cells. As IL-12 is a critical cyto-
kine needed to drive a Th1 response, the loss of DC cells from
the lung may be an important factor in the impaired antipatho-
gen or innate response in the CLP mice challenged with A.
fumigatus. In addition, Barton and Medzhitov [25] have dem-
onstrated a relationship among TLR activation, DCs, and the
manner in which TLR–DCs control the adaptive immune re-
sponse. DC subsets differ from each other via the expression of
distinct sets of pattern-recognition receptors (such as TLRs)
and by the cytokine/chemokines they produce upon matura-
tion. In our immunosuppression model, we are presently ex-
amining whether modification of chemokine levels alters the
presence and/or level of activity of DCs in the lung. Once
again, this type of study may be directly relevant to clinical
sepsis, where it has been shown that DC levels are reduced
[25]. In addition to DCs, monocytes have been identified to
play an interesting role in septic patients, as deactivation of
this cell population has been reported to be associated with
immunosuppression [26]. In particular, monocyte human leu-
kocyte antigen (HLA)-DR expression is down-regulated during
sepsis and is associated with a worse clinical outcome. The
suppression of HLA-DR can be reversed by IFN- treatment,
which in turn improves the clinical course of the disorder.
Fig. 3. A hypothetical sequence of events that leads to the pulmonary immunosuppression observed following sepsis. MA, Macrophages; PMN, polymorphonu-
clear; SIRS, systemic inflammatory response syndrome; CARS, compensatory anti-inflammatory response syndrome.
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CONCLUDING REMARKS
The preceding review suggests that severe diseases with a poor,
long-term outcome may be a result of a dysregulated, inflam-
matory response. Sepsis is a severe acute disease that can
result in immunosuppression, which leads to a secondary in-
fection, thereby amplifying the risk of death. There is a critical
need for mechanistic studies directed at understanding the
immunosuppression induced by sepsis, mostly important for
the elucidation of therapies that could enhance protective
immunity against opportunistic pathogens. Figure 3 outlines
our evolving hypothesis in which a severe, overwhelming in-
nate-immune response by the host (i.e., caused by rupture of
the intestine) against enteric microorganisms affects organs
including the lung. Within the lung, the release of inflamma-
tory mediators such chemokines ultimately leads to a deviation
in the inflammatory response. Although this response is clearly
needed to shut down an exacerbated, inflammatory response as
a result of sepsis, it is ultimately deleterious in the case of a
secondary infectious insult. We also propose that cytokines
(i.e., IL-13, IL-4, IL-10) and chemokines (i.e., C10, MCP-1,
TARC) have major roles in the regulation of TLRs on macro-
phages and DCs during sepsis. The phenotype and activation
state of macrophages may also be affected as described above.
Understanding the cross-talk between soluble mediators and
inflammatory cells may lead to immunotherapies that revert the
immunosuppression and increase the survival rate following
severe sepsis.
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